Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amazon.com Inc (AMZN) vs Cassava Sciences Inc (FLNA) Price & Performance

Amazon.com IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Amazon.com Inc vs Cassava Sciences Inc — how do they compare? Amazon.com Inc trades at $244.66 (market cap $2.64T), while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: Amazon.com Inc is far larger — about 45921× Cassava Sciences Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AMZNFLNA
Market Cap
$2.64T$57.49M
Volume
3,931,282
Sector
Consumer CyclicalHealth
52-Week High
$274.95$4.64
52-Week Low
$198.79$1.16
Enterprise Value
$2.71T-$29.09M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amazon.com Inc

Amazon (AMZN) trades at $245.34, down 0.69% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Recent CEO communications highlight Amazon's AI chip business reaching $20+ billion run-rate and strong visibility into future cash flows from massive capital investments.

Amazon presents a compelling investment case with 88% analyst buy ratings and a $320.75 consensus price target representing 31% upside. Key opportunities include AWS growth and AI leadership, while risks involve intense retail competition and the sustainability of massive capital expenditures. The stock's current valuation at 29.35 P/E appears reasonable given growth trajectory and profitability improvements.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amazon.com Inc

Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.

Read more on AMZN

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA